Skip to main content
Premium Trial:

Request an Annual Quote

Spotfire Plans 2001 Initial Public Offering

NEW YORK, Sept 19 – Spotfire, a developer of analytics software used by pharmaceutical and biotechnology companies, is considering an initial public offering on the Nasdaq next year.

Chris Ahlberg, Spotfire’s CEO, said the Cambridge, Mass.-based company expects to use money from an IPO for general business purposes. He declined to say how much the company hopes to raise.

The IPO would cap a string of offerings by other bioinformatics players. Compugen (Nasdaq: CGEN) of Tel Aviv, Lion Bioscience (Neuer Markt: LIO; Nasdaq: LEON) of Heidelberg, and Rosetta Inpharmatics (Nasdaq: RSTA) all went public this summer. And NetGenics, InforMax, and Genomica are all in the pipeline.

Ahlberg said that Spotfire’s software has broad applications, which should help to expand the company’s revenue bases. Besides biotechnology customers, Spotfire has users in the chemicals, semiconductor, and manufacturing industries.  

The company’s products use a single workspace to combine data, analytical tools, and reporting capabilities needed for decision-making by individuals and groups.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.